Clinical trial NCT04138836: Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
Official title: A 3-Part, Phase 1 Study to Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Participants
Lead sponsor: Bridge Biotherapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: KCRN Research, LLC
First posted: 2019-10-25
Enrollment: 48
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study to determine the effect of multiple-dose BBT-877 on the single-dose pharmacokinetics of midazolam, the safety and tolerability of a single dose of BBT-877 administered alone and with multiple doses of itraconazole, and the effect of multiple-dose esomeprazole on the single-dose pharmacokinetics of BBT-877, in healthy adult subjects.


Eligibility criteria: Inclusion Criteria:

1. Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of age, inclusive, at screening.
2. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dose and throughout the study.
3. BMI ≥ 18.5 and ≤ 32.0 kg/m2 and weight ≥ 50 kg at screening.
4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, as deemed by the PI or designee.
5. No clinically significant history or presence of ECG findings as judged by the PI or qualified designee at screening and first check-in.
6. For a female, must be of non-childbearing potential.
7. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug.
8. If male, must agree to not donate sperm from the first dose until 90 days after the last dose of study drug(s).
9. Must have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures, and be willing and able to comply with the protocol requirements as outlined in the ICF.

Exclusion Criteria:

1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose or regular alcohol consumption within 6 months prior to the first dose.
5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug(s) or related compounds.
6. History of anemia or history of decreased red blood cells (RBC).
7. Estimated creatinine clearance \<80 mL/min at screening.
8. Liver function tests (serum ALT, AST, alkaline phosphatase) and serum bilirubin (total and direct) \> upper limit of normal at screening or first check-in.
9. Baseline hemoglobin, hematocrit, RBC \< lower limit of normal at screening and Day -1 of Period 1.
10. Female subjects who are of childbearing potential.
11. Female subjects who are pregnant or lactating.
12. Positive urine drug or alcohol results at screening or first check-in.
13. Positive urine cotinine at screening.
14. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).

Primary outcomes:
measure: AUC (the area under the curve) [Pharmacokinetics]
timeFrame: Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2
measure: Cmax (peak concentration) [Pharmacokinetics]
timeFrame: Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2
Secondary outcomes:
measure: Plasma LPA (Lysophosphatidic acid) concentration [Pharmacodynamics (Arm 2 and 3)]
timeFrame: Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2
measure: Incidence of adverse events [Safety and tolerability]
timeFrame: Up to 14 days after the last study drug administration
Other outcomes:
Locations:
city: Lincoln
country: United States
facility: Celerion
state: Nebraska
Study officials:
affiliation: Bridge Biotherapeutics, Inc.
name: Jeong-Hyun Ryou, M.D., Ph.D.
role: STUDY_DIRECTOR
References: